Shanghai Zerun Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-05-07
- Employees
- -
- Market Cap
- -
- Website
- http://www.zerunbio.com
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
Phase 3
Completed
- Conditions
- Human Papilloma Virus Infection Type 16Cervical Intraepithelial NeoplasiaHuman Papilloma Virus Infection Type 18
- Interventions
- Biological: HPV-16/18 placeboBiological: HPV-16/18 vaccine
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 12000
- Registration Number
- NCT02733068
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
Phase 1
- Conditions
- Human Papillomavirus
- Interventions
- Biological: HPV 16/18 vaccine, 0,5mlBiological: Placebo control, 0.5mlBiological: HPV 16/18 vaccine, 1.0mlBiological: Placebo control, 1.0ml
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 160
- Registration Number
- NCT01548118
- Locations
- 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath